Equillium, Inc. announced that it has surpassed the interim enrollment target for the Phase 3 EQUATOR study of itolizumab in acute graft-versus-host disease (aGVHD). Equillium expects to deliver the results of the EQUATOR interim data review to Ono during the third quarter, which will then trigger Ono?s three-month option exercise period to acquire Equillium?s rights to itolizumab.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.06 USD | -27.89% | -27.40% | +46.61% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+46.61% | 37.37M | |
+42.83% | 750B | |
+34.11% | 606B | |
-5.70% | 356B | |
+18.06% | 326B | |
+4.63% | 286B | |
+18.34% | 246B | |
-2.86% | 213B | |
+11.31% | 213B | |
+2.43% | 167B |
- Stock Market
- Equities
- EQ Stock
- News Equillium, Inc.
- Equillium, Inc. Announces Interim Enrollment Achieved in Phase 3 EQUATOR Study of Itolizumab in Acute Graft-Versus-Host Disease